Jong-Hee Ko

Title: Jong-Hee Ko: Innovator in Cancer Treatment

Introduction

Jong-Hee Ko is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for cancer and angiogenesis-related diseases. His work focuses on enhancing the effectiveness of therapeutic agents through advanced fusion protein technology.

Latest Patents

Jong-Hee Ko holds a patent for a pharmaceutical composition that includes a fusion protein combining a tumor-penetrating peptide and an anti-angiogenesis agent. This invention aims to prevent and treat cancer or diseases related to angiogenesis. The fusion protein improves the tissue penetrability of the anti-vascular endothelial cell growth factor (anti-VEGF) agent, thereby enhancing its cancer-targeting effects. This innovation demonstrates a remarkable ability to inhibit angiogenesis and offers therapeutic benefits for cancers that show resistance to conventional anti-VEGF treatments. He has 1 patent to his name.

Career Highlights

Jong-Hee Ko is associated with Il Dong Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the pharmaceutical industry, particularly in the realm of cancer therapies.

Collaborations

Jong-Hee Ko collaborates with esteemed colleagues, including Hyuk-Sang Kwon and Young-Min Lee, who contribute to his research initiatives and enhance the scope of his projects.

Conclusion

Jong-Hee Ko's innovative approach to cancer treatment through the development of fusion proteins exemplifies the potential of modern pharmaceuticals to address complex medical challenges. His contributions are paving the way for more effective therapies in the fight against cancer.